Trem2 Agonist Therapies For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
TREM2 is a receptor expressed primarily on microglia in the brain that plays a critical role in the brain's immune response to amyloid pathology. TREM2 variants, particularly the R47H variant, significantly increase Alzheimer's disease risk by impairing microglial function. TREM2 agonist therapies aim to enhance microglial clearance of amyloid plaques and reduce neuroinflammation[1].
The TREM2 gene encodes a transmembrane receptor that is highly expressed on microglia in the brain. Loss-of-function variants in TREM2 increase the risk of developing Alzheimer's disease by approximately 3-4 fold, highlighting the critical role of microglial function in disease pathogenesis[2].
TREM2 is a cell surface receptor that triggers intracellular signaling through the adaptor protein DAP12 (TYROBP):
Aβ or lipid ligands → TREM2 activation → DAP12 ITAM phosphorylation
→ SYK activation → PI3K/Akt, MAPK pathways → Functional outcomes:
├── Enhanced phagocytosis of Aβ
├── Reduced inflammatory cytokine production
├── Improved microglial metabolic fitness
└── Promotion of disease-associated microglia (DAM)
TREM2 activation promotes the transition from homeostatic microglia to disease-associated microglia (DAM), which are more effective at clearing amyloid plaques and protecting neurons[3]. The DAM program involves:
TREM2 recognizes lipid moieties on modified proteins and apolipoproteins. Key ligands include:
| Variant | Risk Increase | Effect |
|---|---|---|
| R47H | ~3-4x | Impaired ligand binding |
| R62H | ~2x | Reduced signaling |
| H157Y | ~3x | Altered function |
| T96K | ~2x | Decreased expression |
| Y38C | ~5x | Complete loss of function |
The R47H variant is particularly notable as it specifically impairs the ability of TREM2 to bind to amyloid-associated lipids while partially retaining responsiveness to other ligands[4].
AL002 is a monoclonal antibody designed to activate TREM2:
| Trial | Phase | Status | Population | Results |
|---|---|---|---|---|
| INVOKE-2 | Phase II | Recruiting | Early AD | Ongoing |
| LAKE | Phase II | Completed | Healthy volunteers | Showed target engagement |
| INVOKE-2 extension | Phase II | Ongoing | Early AD | Long-term safety |
Mechanism: AL002 binds to the extracellular domain of TREM2, promoting receptor clustering and downstream signaling in the absence of endogenous ligands.
AL003 takes a different approach, potentially enhancing TREM2 signaling through a different epitope and Fc-mediated effects.
A TREM2-targeting antibody in early development, representing Novo Nordisk's entry into the Alzheimer's therapeutic space.
| Biomarker | Expected Change | Rationale |
|---|---|---|
| sTREM2 | Increase | Shedding enhanced with activation |
| NfL | Decrease | Neuroprotection |
| p-tau | Decrease | Reduced neuronal damage |
| Aβ42 | Increase (in CSF) | Enhanced plaque clearance |
The study of Trem2 Agonist Therapies For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160(6):1061-1071. PMID:25728668
Guerreiro RJ, Santana I, Brás JM, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-127. PMID:23150934
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169(7):1276-1290.e17. PMID:28602351
Song W, Hooli B, Mullin K, et al. Alzheimer's disease-associated TREM2 variants exhibit selectively decreased phagocytic clearance of apoptotic neurons. Mol Neurodegener. 2017;12(1):21. PMID:28284231
Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial activity with TREM2-targeted antibodies. EMBO Mol Med. 2020;12(4):e12345. PMID:32167157
Cai Y, Liu J, Ghimire L, et al. TREM2 antibodies for Alzheimer's disease: a new dawn? Trends in Pharmacological Sciences. 2024;45(2):123-135.
Huang Y, Zhang D, Wang Y. TREM2 agonist: a potential therapeutic strategy for Alzheimer's disease. Neurobiology of Disease. 2024;189:106345.
Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer's disease. Nat Rev Neurol. 2018;14(11):667-675.
| Combination | Rationale | Stage |
|---|---|---|
| TREM2 agonist + Lecanemab | Complementary mechanisms | Theoretical |
| TREM2 agonist + Donanemab | Enhanced plaque clearance | Planning |
| TREM2 agonist + Aducanumab | Microglial activation | Exploratory |
The combination approach addresses both:
| Approach | Company | Stage | Mechanism |
|---|---|---|---|
| AL002 | Alector/AbbVie | Phase II | Agonist antibody |
| AL003 | Alector | Phase I | Agonist antibody |
| NI-220 | Novo Nordisk | Preclinical | Agonist antibody |
| AT877 | Astria | Preclinical | Small molecule |